EUVIMEDEUVIMED entdecken
Crossref

Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors

Yang Jiao, Guoge Li, Kelin Chen, Chunqing Shao, Zhijun Yang, Guojun Zhang

Journal of Endocrinological Investigation · 2026

DOI: 10.1007/s40618-026-02816-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, 2026. Verfasst von Yang Jiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Chemokines, CC, Neoplasm Recurrence, Local, Neuroendocrine Tumors, Pituitary Neoplasms. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Beijing Hospitals Authority's Ascent Plan, Laboratory for Clinical Medicine, Capital Medical University, Beijing Hospitals Authority’s Ascent Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study aimed to investigate the predictive value of serum CCL18 in the recurrence and invasiveness of pituitary neuroendocrine tumors (PitNETs). CCL18, a chemokine secreted mainly by tumor-associated macrophages, has been implicated in cancer progression, but its role in PitNETs remains unexplored. METHOD: A total of 463 patients with PitNETs (110 recurrent and 353 non-recurrent) who underwent surgery at Beijing Tiantan Hospital between 2020 and 2022, along with 32 healthy controls, were retrospectively analyzed. Serum CCL18 concentrations were measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Cat# DCC180). Clinical, radiological, and pathological parameters were assessed, and subgroup analyses were performed according to recurrence and invasiveness. Statistical analyses were conducted using SPSS 26.0, and receiver operating characteristic (ROC) curves were generated with GraphPad Prism 8.0. In addition, CCL18 mRNA expression in recurrence PitNETs and non-recurrence PitNETs tissues was validated by quantitative real-time PCR (qPCR). RESULTS: Serum CCL18 was higher in recurrent than non-recurrent PitNETs (median: 46253 vs. 27834 pg/mL, P < 0.001) and elevated in invasive tumors. ROC analysis showed an AUC of 0.801 (95% CI: 0.752–0.850), with 84.9% sensitivity and 79.2% specificity for recurrence. CCL18 correlated with Knosp grade and Ki-67 index (P < 0.001) and remained an independent predictor in multivariate analysis. qRT-PCR revealed CCL18 mRNA was upregulated in recurrence PitNET tissues versus non-recurrence PitNETs tissues (P < 0.001), suggesting systemic elevation may reflect tumor microenvironment secretion. Recurrent invasive PitNETs had the highest CCL18 levels. CONCLUSIONS: Serum CCL18 is associated with PitNETs recurrence and invasiveness and may serve as a non-invasive biomarker. Combined tissue and serum assessment could improve risk stratification and prognostic evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokines, CCNeoplasm Recurrence, LocalNeuroendocrine TumorsPituitary NeoplasmsBiomarkers, TumorHumansFemaleMaleNeoplasm InvasivenessMiddle AgedRetrospective StudiesPrognosisAdultPredictive Value of TestsCase-Control StudiesROC CurveFollow-Up Studies

Stichwörter der Autor:innen

BiomarkerCCL18Diagnostic valueInvasionPituitary neuroendocrine tumorRecurrence

Substanzen

CCL18 protein, humanChemokines, CCBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Beijing Engineering Research Center of Immunological Reagents Clinical Research, Beijing, China.
  • NMPA Key Laboratory for Quality Control of In Vitro Diagnostic, Beijing, China.
  • Laboratory diagnosis platform for nervous system infectious diseases, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100070, China.
  • Department of Neurosurgery of Beijing Tiantan Hospital, Capital Medical University, Beijing, China. zhijunyang@ccmu.edu.cn.
  • , No.119, South Fourth Ring West Road, Fengtai District, Beijing, 100070, China. zhijunyang@ccmu.edu.cn.

Förderung

  • Beijing Hospitals Authority's Ascent Plan
  • Laboratory for Clinical Medicine, Capital Medical University
  • Beijing Hospitals Authority’s Ascent Plan

Zitieren

APA

Jiao, Y., Li, G., Chen, K., Shao, C., Yang, Z., & Zhang, G. (2026). Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-026-02816-4

Vancouver

Jiao Y, Li G, Chen K, Shao C, Yang Z, Zhang G. Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors. Journal of Endocrinological Investigation. 2026. doi:10.1007/s40618-026-02816-4

BibTeX
@article{Jiao2026,
  author = {Jiao, Yang and Li, Guoge and Chen, Kelin and Shao, Chunqing and Yang, Zhijun and Zhang, Guojun},
  title = {Predictive value of serum CCL18 for recurrence and invasiveness in pituitary neuroendocrine tumors},
  journal = {Journal of Endocrinological Investigation},
  year = {2026},
  doi = {10.1007/s40618-026-02816-4}
}
Kostenlos starten →